Research models and mesenchymal/epithelial plasticity of osteosarcoma
Open Access
- 22 May 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell & Bioscience
- Vol. 11 (1), 1-12
- https://doi.org/10.1186/s13578-021-00600-w
Abstract
Most osteosarcomas (OSs) develop from mesenchymal cells at the bone with abnormal growth in young patients. OS has an annual incidence of 3.4 per million people and a 60–70% 5-year surviving rate. About 20% of OS patients have metastasis at diagnosis, and only 27% of patients with metastatic OS survive longer than 5 years. Mutation of tumor suppressors RB1, TP53, REQL4 and INK4a and/or deregulation of PI3K/mTOR, TGFβ, RANKL/NF-κB and IGF pathways have been linked to OS development. However, the agents targeting these pathways have yielded disappointing clinical outcomes. Surgery and chemotherapy remain the main treatments of OS. Recurrent and metastatic OSs are commonly resistant to these therapies. Spontaneous canine models, carcinogen-induced rodent models, transgenic mouse models, human patient-derived xenograft models, and cell lines from animal and human OSs have been developed for studying the initiation, growth and progression of OS and testing candidate drugs of OS. The cell plasticity regulated by epithelial-to-mesenchymal transition transcription factors (EMT-TFs) such as TWIST1, SNAIL, SLUG, ZEB1 and ZEB2 plays an important role in maintenance of the mesenchymal status and promotion of cell invasion and metastasis of OS cells. Multiple microRNAs including miR-30/9/23b/29c/194/200, proteins including SYT-SSX1/2 fusion proteins and OVOL2, and other factors that inhibit AMF/PGI and LRP5 can suppress either the expression or activity of EMT-TFs to increase epithelial features and inhibit OS metastasis. Further understanding of the molecular mechanisms that regulate OS cell plasticity should provide potential targets and therapeutic strategies for improving OS treatment.Funding Information
- National Institutes of Health (R01 CA193455)
This publication has 131 references indexed in Scilit:
- Snail2 promotes osteosarcoma cell motility through remodelling of the actin cytoskeleton and regulates tumor developmentCancer Letters, 2013
- Schedule‐dependent therapeutic efficacy of L19mTNF‐α and melphalan combined with gemcitabineCancer Medicine, 2013
- Endothelin-1 Promotes Osteosarcoma Cell Invasion and Survival against Cisplatin-induced ApoptosisClinical Orthopaedics and Related Research, 2011
- Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancyTumor Biology, 2011
- Integrated Proteomics and Genomics Analysis Reveals a Novel Mesenchymal to Epithelial Reverting Transition in Leiomyosarcoma through Regulation of SlugMolecular & Cellular Proteomics, 2010
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly personsInternational Journal of Cancer, 2009
- Osteoblastic and Osteolytic Human Osteosarcomas can be Studied With a New Xenograft Mouse Model Producing Spontaneous MetastasesCancer Investigation, 2009
- Current strategies of chemotherapy in osteosarcomaInternational Orthopaedics, 2006
- Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesisNature, 1992